2012
DOI: 10.1158/0008-5472.can-11-3873
|View full text |Cite
|
Sign up to set email alerts
|

Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche

Abstract: Hypoxia within a tumor acts as a strong selective pressure that promotes angiogenesis, invasion, and metastatic spread. In this study, we used immune competent bone marrow chimeric mice and syngeneic orthotopic mammary cancer models to show that hypoxia in the primary tumor promotes premetastatic niche formation in secondary organs. Injection of mice with cell-free conditioned medium derived from hypoxic mammary tumor cells resulted in increased bone marrow-derived cell infiltration into the lung in the absenc… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
278
0
4

Year Published

2013
2013
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 315 publications
(287 citation statements)
references
References 20 publications
0
278
0
4
Order By: Relevance
“…Since no changes in CLP were observed in the bone marrow ( Supplementary Fig. 8B), it is possible that these T cell changes are a consequence of the increased Gr1 þ cell numbers as the latter have been shown previously to have immune suppressive properties 23,24 . Metastasis and neutrophil recruitment are dependent on complex cytokine networks.…”
Section: Fak Deficiency Shifts Hscs Towards a Myeloid Commitmentmentioning
confidence: 80%
See 1 more Smart Citation
“…Since no changes in CLP were observed in the bone marrow ( Supplementary Fig. 8B), it is possible that these T cell changes are a consequence of the increased Gr1 þ cell numbers as the latter have been shown previously to have immune suppressive properties 23,24 . Metastasis and neutrophil recruitment are dependent on complex cytokine networks.…”
Section: Fak Deficiency Shifts Hscs Towards a Myeloid Commitmentmentioning
confidence: 80%
“…MDSCs are a mixture of myeloid cells with characteristics of monocytes and granulocytes and are generally described by the co-expression of the mouse markers CD11b and Gr1 (CD11b þ Gr1 þ ) 21,22 . Their expansion at metastatic sites generates an immunosuppressive niche that suppresses T cell activation, proliferation and cytotoxicity and also suppresses NK cell cytotoxicity [23][24][25][26] . These cells have been shown to facilitate tumour cell seeding and colonization at metastatic sites and are thereby thought to drive metastasis [27][28][29] .…”
mentioning
confidence: 99%
“…Furthermore, Kowanetz et al [26] showed that depletion of Gr1 + or Ly6G + cells from the pre-metastatic lung results in reduced metastasis. Similarly, Sceneay et al [304] also observed increased numbers of granulocytic CD11b + Ly6C med Ly6G + myeloid cells in the pre-metastastic lungs in mice injected with melanoma or breast carcinoma cells with a concomitant reduction in the cytotoxic activity of NK cells [304]. Erler et al [305] observed that lysyl oxidase (LOX) secreted by hypoxic breast tumor cells is required for the recruitment of immature myeloid CD11b + F4/80 − cells to the premetastatic lung.…”
Section: Neutrophils In Pre-metastatic Organs -The "Seed and Soil" Hymentioning
confidence: 96%
“…As Ly6G1 granulocytic polymorphonuclear neutrophil subsets of myeloid-derived suppressor cells (PMN-MDSC) reportedly impair NK cell development specifically [38][39][40] and as cross-talk between tumor-associated macrophages and MDSCs has been shown to sustain and exacerbate immune suppression in the tumor microenvironment, 41 we tested whether this population was also involved in preventing NK cell expansion induced by CpG-ODN aerosol. Four groups of mice (5 mice/group) were injected with B16 cells as above and, 96 hr later, treated every 72-96 hr with the Ly6G-specific mAb (1A8), which recognizes and depletes Ly6Ghigh neutrophilic populations, or with isotype control.…”
Section: Anti-tumor Activity Of Aerosol Cpg-odn Treatment Against B16mentioning
confidence: 99%